Allergy & Immunology
Guideline: Diagnosis and Evaluation of Hypersensitivity Pneumonitis
22 Apr, 2021 | 08:21h | UTCSee also: Executive Summary
Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease
22 Apr, 2021 | 08:40h | UTC
Commentaries on Twitter
Early data from @RCHMelbourne show that, at 3-6 month follow-up, all 151 children with mild and asymptomatic #COVID19 had returned to their baseline health status and post-acute COVID-19 symptoms had resolved.
Letter from @Shidan_Tosif & colleagues: https://t.co/XXa0EPIgPY
— The Lancet Child & Adolescent Health (@LancetChildAdol) April 20, 2021
Given such little available data, this study from Australia on post-acute COVID-19 symptoms in children is very important
Findings are extremely reassuring
Post-acute symptoms were rare, and mild (cough 4%, fatigue 2%, cough and fatigue 1%)
Great news!https://t.co/TEJyES3Crx
— Alasdair Munro (@apsmunro) April 21, 2021
Great to see research looking at whether long Covid is a problem in children.
From this Melbourne cohort, enduring cough and fatigue are uncommon.
It hasn’t been clear to me whether borders will reopen before children are vaccinated so this is VIP https://t.co/iLXqwXJmOt
— Jin Russell (@DrJinRussell) April 21, 2021
Truly encouraging data on post-acute #COVID19 in children. Single-center in Australia. n=151.
8% post-acute symptoms – all symptomatic COVID-19.
Mild symptoms: cough 4%, fatigue 2%, both 1%. Duration: cough 3-8w; post-viral fatigue 6-8w. All solved in follow-up time 3-6 months. https://t.co/vKrEFZlw3C— Pablo Guisado Vasco (@PabloGVasco) April 21, 2021
ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
21 Apr, 2021 | 07:11h | UTCSee also: Diagnostic Flow Chart
Commentary on Twitter
The ISTH has released interim guidance on vaccine-induced immune thrombotic thrombocytopenia (#VITT) to inform the management of suspected thrombosis in subjects who have recently received the AstraZeneca or Johnson & Johnson vaccine. https://t.co/qqtQtpywaf pic.twitter.com/wNmjNNDs4z
— ISTH (@isth) April 20, 2021
COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
21 Apr, 2021 | 07:07h | UTCCommentary: Johnson & Johnson vaccine: EU regulator says blood clot very rare side effect – BBC
Commentary on Twitter
https://twitter.com/hildabast/status/1384535676482297865
[News release – not published yet] Sputnik V demonstrates 97.6% efficacy according to the analysis of data of 3.8 million vaccinated persons in Russia
20 Apr, 2021 | 06:08h | UTC
Commentary on Twitter
https://twitter.com/hildabast/status/1384270692946878471
Pfizer CEO says third Covid vaccine dose likely needed within 12 months
20 Apr, 2021 | 06:02h | UTCPfizer CEO says third Covid vaccine dose likely needed within 12 months – CNBC
Commentary: Fully Vaccinated? Get Ready For Your Third Dose – Forbes
China’s Sinovac COVID-19 vaccine 67% effective in preventing symptomatic infection, 85% effective in preventing hospitalizations and 80% effective in preventing deaths – Chile govt report
18 Apr, 2021 | 21:45h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1383183542495039490
Study shows antihistamines may impair response to exercise training
16 Apr, 2021 | 06:06h | UTCCommentary: Histamine-suppressing drugs found to reduce benefits of exercise – MedicalXpress
Commentary on Twitter (thread – click for more)
Extremely excited to finally share our newest paper: Histamine H1 and H2 receptors are essential transducers of the integrative exercise training response in humans. Published today in @ScienceAdvances. A thread: (1/12)https://t.co/R4FNiKWyG9 pic.twitter.com/U2HFHOY9eA
— Thibaux Van der Stede (@ThibauxV) April 14, 2021
[Preprint] Risk of rare blood clotting much higher for COVID-19 than for vaccines
16 Apr, 2021 | 06:37h | UTCNews release: Risk of rare blood clotting higher for COVID-19 than for vaccines – University of Oxford
Original study (preprint): Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine
Commentaries: Brain clots ‘more likely’ with Covid infection than vaccine – BBC AND Risk for Cerebral Venous Thrombosis Elevated After COVID-19 Diagnosis – NEJM Journal Watch AND Study: COVID much more likely than vaccines to cause blood clots – CIDRAP
Commentary on Twitter
There is an interesting new preprint out that will probably generate a lot of coverage at least in the UK. Essentially it argues that the risk of CVST is much higher from #covid19 than from vaccines.
Quick thread on this:https://t.co/0MdDU2z9bp— Kai Kupferschmidt (@kakape) April 15, 2021
Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine
15 Apr, 2021 | 07:02h | UTCThrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine
Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation
Diagnosis and management of leukocytoclastic vasculitis
14 Apr, 2021 | 01:26h | UTCDiagnosis and management of leukocytoclastic vasculitis – Internal and Emergency Medicine
RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19
13 Apr, 2021 | 05:30h | UTCOriginal study (preprint): Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial – medRxiv
Commentary: Covid: Asthma drug ‘speeds up recovery at home’ – BBC
Related study: Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19 (study and commentaries)
[Preprint] Pfizer vaccine less effective for SARS-CoV-2 variant B.1.351
12 Apr, 2021 | 01:26h | UTCCommentaries: South African variant may evade protection from Pfizer vaccine, Israeli study says – Reuters AND Israeli data shows South African variant able to ‘break through’ Pfizer vaccine – The Times of Israel
Related: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.
Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine
12 Apr, 2021 | 01:20h | UTCPapers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine – TCTMD
Study 1: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination – New England Journal of Medicine
Study 2: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination – New England Journal of Medicine
[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil
9 Apr, 2021 | 03:36h | UTC
Commentary on Twitter (thread – click for more)
New 50% efficacy study of Brazil-predominant vaccine CoronaVac (by Sinovac) in Manaus 🇧🇷 among healthcare workers when #P1 ~75% dominant. Not a trial, but the study found a 1st dose >=14-days efficacy of 50% on symptomatic #COVID19, ~32% if +asymptomatic. https://t.co/YMmZ3mmSDI pic.twitter.com/jwx5R627ys
— Eric Feigl-Ding (@DrEricDing) April 8, 2021
The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19
9 Apr, 2021 | 03:35h | UTC
Editorial by Dr. Antony Fauci: The story behind COVID-19 vaccines
9 Apr, 2021 | 03:32h | UTCThe story behind COVID-19 vaccines – Science
UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca
8 Apr, 2021 | 09:05h | UTC
Commentary on Twitter
Following suspensions by some countries of the COVID-19 Vaccine AstraZeneca over suspected blood clots, the MHRA confirms that the benefits of the vaccine in preventing COVID-19 far outweigh the risks. People should still go and get their COVID-19 vaccine https://t.co/zse5RUIct1
— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) April 7, 2021
WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed
8 Apr, 2021 | 09:09h | UTC
Commentary on Twitter (thread – click for more)
🆕 Interim statement of the #COVID19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on the AstraZeneca vaccine https://t.co/p8XMMAiUne pic.twitter.com/7DMRNFxQsX
— World Health Organization (WHO) (@WHO) April 7, 2021
AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. The benefits of the vaccine continue to outweigh the risks for people who receive it.
8 Apr, 2021 | 09:07h | UTCCommentaries: In rare instances, AstraZeneca’s Covid-19 vaccine linked to blood clots, regulators say – STAT AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre
JCVI statement on use of the AstraZeneca COVID-19 vaccine: “JCVI currently advises that it is preferable for adults aged <30 years to be offered an alternative COVID-19 vaccine, if available.”
8 Apr, 2021 | 09:02h | UTCJCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021 – GOV.UK
Commentaries: Covid: Under-30s offered alternative to Oxford-AstraZeneca jab – BBC AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre
Differences in susceptibility of circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 to neutralization by convalescent plasma or vaccinee (Sinopharm or Sinovac) serum
7 Apr, 2021 | 01:57h | UTCRelated studies: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination – Nature Medicine AND Pfizer coronavirus vaccine found to be moderately less effective against B.1.351 variant AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well. AND RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant AND New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments AND Moderna COVID-19 vaccine may be less effective against variant found in South Africa
Commentary on Twitter
https://twitter.com/hildabast/status/1379597338956603400
Antibody persistence for at least 6 months after the second dose of mRNA vaccine (Moderna) for Covid-19
7 Apr, 2021 | 01:54h | UTCCommentary: Moderna COVID Vaccine Offers Protection for at Least 6 Months: Study – HealthDay
Related: [Press release – not published yet] Pfizer/BioNTech vaccine is 91% effective for at least 6 months
Commentary on Twitter
Very good neutralizing antibody levels for at least 7 months after 2 doses of mRNA vaccine (and likely years)@NEJM today https://t.co/3KQmiuvEJq pic.twitter.com/cp2htnr76E
— Eric Topol (@EricTopol) April 6, 2021
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines
6 Apr, 2021 | 01:21h | UTCReactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines – JAMA
Commentaries on Twitter
This @JAMA_current paper summarizes adverse reactions to mRNA #COVID19 vaccines through @CDCgov v-safe surveillance system, which collects near–real-time data via smartphone text message prompts and web-based health surveys. https://t.co/Xbdg0lxYfK pic.twitter.com/E4q13aJfkZ
— Muin J. Khoury (@MuinJKhoury) April 5, 2021
.@CDCgov's v-safe program collects near–realtime data from US #COVID19 vaccine recipients. V-safe participants self-enroll and receive smartphone text messages to initiate web-based health health surveys from the day of vaccination (day 0) through 12 mo https://t.co/utJNibTTd9
— JAMA (@JAMA_current) April 5, 2021
Perspective | Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination
5 Apr, 2021 | 01:39h | UTCConcerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination – Nature
Commentary on Twitter
A concern raised about delaying the 2nd vaccine dose is the potential to promote immune escape, new mutations. A new @NatRevImmunol essay argues against that possibility (may even be the opposite) https://t.co/XlCOP5DwTf by @sarahcobey @DanLarremore @yhgrad @mlipsitch pic.twitter.com/ehVOPX9sQv
— Eric Topol (@EricTopol) April 2, 2021